Antimicrobial stewardship

Sort by: Newest first Oldest first A-Z Z-A

Accurately diagnosing antibiotic allergies Subscription

Diagnosing true drug allergy can be challenging and it is important that patients are managed appropriately.
How precarious antibiotic supplies are putting patients at risk Subscription

The antibiotic supply chain is “at risk of collapsing”, which could lead to major problems treating serious infections and add to resistance levels.
Pharmacy’s role in antimicrobial resistance and stewardship Subscription

This article summarises the evidence supporting the role of pharmacists and pharmacy teams in antimicrobial stewardship and outlines the impact of their activities.
The global race to combat antimicrobial resistance Subscription

The Longitude Prize has relaunched after 300 years and this time teams around the world are racing to develop a rapid point-of-care diagnostic test that will help prevent the overuse of antibiotics and put them in the running to win £8m.
2017: Pharmacy's roller-coaster year Subscription

It has been an unsettling 12 months for pharmacy and as 2017 draws to a close there are still a number of unresolved issues hanging over the New Year.
AMR and diagnostics: pointing the way to better infection control Subscription

Antimicrobial resistance — the ability of previously sensitive microorganisms to resist the effects of an antimicrobial agent — is a growing problem. The World Health Organization has warned that we could be moving into a post-antibiotic era where even minor injuries could lead to life-threatening infections, consequently putting an end to complex surgery and returning us to an era where childbirth is high-risk.
Antimicrobial therapies for Gram-positive infections Subscription

Gram-positive bacteria are among the most common human pathogens associated with clinical infections, which range from mild skin infections to sepsis. In an era defined by antimicrobial resistance (AMR) and an increasing drive toward delivering patient care via ambulatory pathways, the paradigm for the management of infections is changing. Methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE), the best known cases of ...
Ceftazidime-avibactam: a novel cephalosporin/β-lactamase inhibitor Subscription

Over the past decade, infections caused by multidrug-resistant Gram-negative organisms have increased. The limited availability in treatment options for these infections prompted both the UK to create a five-year antimicrobial resistance strategic plan to stimulate the development of new antibiotics, and the Infectious Diseases Society of America to call for ten new antimicrobial agents to be developed by 2020. Ceftazidime-avibactam is a combination of a third-generation ...
Fluoroquinolones for treating tuberculosis Subscription

Tuberculosis (TB) remains a significant global health and socioeconomic challenge. The duration of current anti-TB therapies, the adverse effects of certain anti-TB drugs and the growing problem of drug-resistant TB on an international scale mean that it is imperative for new, effective and safe treatment regimens to be developed. Fluoroquinolones are a class of drugs that have been used in the treatment of TB for several decades. This article provides an overview of the current treatment ...
Clostridium difficile: diagnosis and treatment update Subscription

There are around 12,000 cases of Clostridium difficile infection (CDI) each year in the UK and during 1999 to 2007, deaths from CDI peaked at around 4,000 per year. This article summarises diagnosis and management, as well as the current therapeutic options for CDI, including faecal microbiota transplant.